本帖最后由 老马 于 2012-1-13 21:20 编辑 + g l# K) t+ p0 x+ L: z
8 b9 t0 Q6 f1 Q; L- ]$ S爱必妥和阿瓦斯丁的比较
. I& j% x8 T9 p! l( {; s a
% W; Y- l, B" H6 t' g8 {) O1 zhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/' n7 A% l1 ^9 e* `
6 X7 L8 l0 Z! j8 a* Y9 u# C4 T$ @
0 W: D, z: d# ?3 h- b
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
# P2 r/ Q5 l7 i==================================================
5 T& |) z' t* ?' X" `! ~9 M& COverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
! M% {; l; T* P6 F. m9 n- l& NPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.2 ^3 E& j& `0 M+ A; T) ^4 T
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
+ M) B+ b8 @, A# N, W! Z
|
显身卡
; h) P; M" I$ k2 a/ f
